Literature DB >> 9815614

Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization.

H M Ross1, L W Weber, S Wang, G Piskun, R Dyall, P Song, Y Takechi, J Nikolić-Zugić, A N Houghton, J J Lewis.   

Abstract

DNA immunization has been shown to elicit both antibody and CTL responses against antigens expressed by infectious organisms. Because CTL responses have been implicated in rejection of cancer, we investigated whether DNA immunization by particle bombardment using a gene gun could induce CTL responses that were capable of rejecting tumors in mice. DNA immunization by particle bombardment using genes encoding beta-galactosidase and ovalbumin primed mice to generate CTLs in two genetic backgrounds (DBA/2 and C57BL/6 strains, respectively). DNA immunization was more potent in inducing CTLs than immunization with an optimized regimen of ovalbumin peptide plus immune adjuvant. Immunity induced by DNA immunization protected mice against s.c. challenge with tumors expressing the beta-galactosidase antigen. Tumors were rejected even when DNA immunization was started 3 or 7 days after tumor challenge as tumors were becoming established. Tumor rejection required CD8(+) T cells, confirming a role for CTLs in vivo. These studies show that DNA immunization by particle bombardment can efficiently induce CTL responses that are capable of rejecting even established tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815614

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Authors:  Polly D Gregor; Jedd D Wolchok; Vandana Turaga; Jean-Baptiste Latouche; Michel Sadelain; Dean Bacich; Warren D W Heston; Alan N Houghton; Howard I Scher
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

2.  Tumor immunity and autoimmunity induced by immunization with homologous DNA.

Authors:  L W Weber; W B Bowne; J D Wolchok; R Srinivasan; J Qin; Y Moroi; R Clynes; P Song; J J Lewis; A N Houghton
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

3.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

4.  Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

Authors:  Robert R Jenq; Christopher G King; Christine Volk; David Suh; Odette M Smith; Uttam K Rao; Nury L Yim; Amanda M Holland; Sydney X Lu; Johannes L Zakrzewski; Gabrielle L Goldberg; Adi Diab; Onder Alpdogan; Olaf Penack; Il-Kang Na; Lucy W Kappel; Jedd D Wolchok; Alan N Houghton; Miguel-Angel Perales; Marcel R M van den Brink
Journal:  Blood       Date:  2008-11-14       Impact factor: 22.113

5.  Heteroclitic immunization induces tumor immunity.

Authors:  R Dyall; W B Bowne; L W Weber; J LeMaoult; P Szabo; Y Moroi; G Piskun; J J Lewis; A N Houghton; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

6.  Enhanced responses to tumor immunization following total body irradiation are time-dependent.

Authors:  Adi Diab; Robert R Jenq; Gabrielle A Rizzuto; Adam D Cohen; Deonka W Huggins; Taha Merghoub; Manuel E Engelhorn; José A Guevara-Patiño; David Suh; Vanessa M Hubbard-Lucey; Adam A Kochman; Suzie Chen; Hong Zhong; Jedd D Wolchok; Marcel R M van den Brink; Alan N Houghton; Miguel-Angel Perales
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.